GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Debt-to-EBITDA

Formycon AG (XTER:FYB) Debt-to-EBITDA : -0.86 (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Formycon AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1.23 Mil. Formycon AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €9.63 Mil. Formycon AG's annualized EBITDA for the quarter that ended in Jun. 2024 was €-12.66 Mil. Formycon AG's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.86.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Formycon AG's Debt-to-EBITDA or its related term are showing as below:

XTER:FYB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.42   Med: 0.18   Max: 0.76
Current: 0.17

During the past 13 years, the highest Debt-to-EBITDA Ratio of Formycon AG was 0.76. The lowest was -0.42. And the median was 0.18.

XTER:FYB's Debt-to-EBITDA is ranked better than
77.78% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs XTER:FYB: 0.17

Formycon AG Debt-to-EBITDA Historical Data

The historical data trend for Formycon AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Debt-to-EBITDA Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.42 0.76 0.36

Formycon AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.35 0.44 0.21 -0.86

Competitive Comparison of Formycon AG's Debt-to-EBITDA

For the Biotechnology subindustry, Formycon AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Formycon AG's Debt-to-EBITDA falls into.



Formycon AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Formycon AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(21.671 + 7.815) / 81.037
=0.36

Formycon AG's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.233 + 9.631) / -12.658
=-0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Formycon AG  (XTER:FYB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Formycon AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Formycon AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Nicola Mikulcik Board of Directors
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG Headlines

No Headlines